Our Dr. Lake: Bottom of profile: Dr. Lake also
Post# of 148188
(Total Views: 444)
Posted On: 10/10/2024 9:48:05 PM
Our Dr. Lake:
Bottom of profile:
Dr. Lake also serves leadership positions in the NIH-funded MACS/WIHS Combined Cohort Study and AIDS Clinical Trials Group.
https://www.cytodyn.com/our-team/scientific-advisory-board
...
The MWCCS is a collaborative research effort that aims to understand and reduce the impact of chronic health conditions—including heart, lung, blood, and sleep (HLBS) disorders—that affect people living with HIV.
cohort participants in the Characteristics of the MACS/WIHS Combined Cohort Study: Opportunities for Research on Aging with HIV in the Longest US Observational Study of HIV article.
Major areas of investigation include:
Cardiovascular and pulmonary
Neuropsychological
Aging
Cancer
Psychosocial
Health disparities
https://statepi.jhsph.edu/mwccs/about-mwccs/
Clicking on the study paper in above link:
In 2019, the National Institutes of Health combined the Multicenter AIDS Cohort Study (MACS) and the Women’s Interagency HIV Study (WIHS) into the MACS/WIHS Combined Cohort Study (MWCCS).
In April 2019 the MACS and WIHS, which were primarily funded by the National Institute of Allergy and Infectious Diseases, were merged to form the MACS/WIHS Combined Cohort Study (MWCCS) (4–6), with primary stewardship by the National Heart, Lung, and Blood Institute and cofunding provided by 13 additional institutes of the National Institutes of Health (NIH).
At the time of this merger, they were the longest-running observational studies of PLWH in the United States.
...
Cytodyn Feb. 1st, 2024:
CytoDyn’s CEO, Dr. Jacob Lalezari stated, “Our HIV protocol has been revised and resubmitted following FDA input, and will study leronlimab in HIV patients who have increased inflammation and immune activation, which causes heart attacks, strokes, and other vascular events. We believe this protocol will help clarify the mechanisms by which leronlimab can be used as an immune modulator in HIV and a variety of other therapeutic areas.”
https://www.cytodyn.com/newsroom/press-releas...rotocol-to
____
Aug. 23rd, 2024
“We are looking forward to working with Syneos Health to advance our Phase II study of leronlimab’s effects on chronic inflammation. With the company’s support, our goal is to generate clinical data that we believe will affirm the utility of leronlimab in addressing a number of medical concerns impacting patients globally,” said Dr. Jacob Lalezari, CEO.
____
Dr. Lake is our gateway to a vast database of HIV related conditions, designing our inflammation protocol.
Bottom of profile:
Dr. Lake also serves leadership positions in the NIH-funded MACS/WIHS Combined Cohort Study and AIDS Clinical Trials Group.
https://www.cytodyn.com/our-team/scientific-advisory-board
...
The MWCCS is a collaborative research effort that aims to understand and reduce the impact of chronic health conditions—including heart, lung, blood, and sleep (HLBS) disorders—that affect people living with HIV.
cohort participants in the Characteristics of the MACS/WIHS Combined Cohort Study: Opportunities for Research on Aging with HIV in the Longest US Observational Study of HIV article.
Major areas of investigation include:
Cardiovascular and pulmonary
Neuropsychological
Aging
Cancer
Psychosocial
Health disparities
https://statepi.jhsph.edu/mwccs/about-mwccs/
Clicking on the study paper in above link:
In 2019, the National Institutes of Health combined the Multicenter AIDS Cohort Study (MACS) and the Women’s Interagency HIV Study (WIHS) into the MACS/WIHS Combined Cohort Study (MWCCS).
In April 2019 the MACS and WIHS, which were primarily funded by the National Institute of Allergy and Infectious Diseases, were merged to form the MACS/WIHS Combined Cohort Study (MWCCS) (4–6), with primary stewardship by the National Heart, Lung, and Blood Institute and cofunding provided by 13 additional institutes of the National Institutes of Health (NIH).
At the time of this merger, they were the longest-running observational studies of PLWH in the United States.
...
Cytodyn Feb. 1st, 2024:
CytoDyn’s CEO, Dr. Jacob Lalezari stated, “Our HIV protocol has been revised and resubmitted following FDA input, and will study leronlimab in HIV patients who have increased inflammation and immune activation, which causes heart attacks, strokes, and other vascular events. We believe this protocol will help clarify the mechanisms by which leronlimab can be used as an immune modulator in HIV and a variety of other therapeutic areas.”
https://www.cytodyn.com/newsroom/press-releas...rotocol-to
____
Aug. 23rd, 2024
“We are looking forward to working with Syneos Health to advance our Phase II study of leronlimab’s effects on chronic inflammation. With the company’s support, our goal is to generate clinical data that we believe will affirm the utility of leronlimab in addressing a number of medical concerns impacting patients globally,” said Dr. Jacob Lalezari, CEO.
____
Dr. Lake is our gateway to a vast database of HIV related conditions, designing our inflammation protocol.
(5)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼